FDC growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+3.0%+6.8%
EBITDA+6.6%+11.3%
Net Income+5.5%+13.2%
EPS (adj.)+5.5%+13.2%
Total Assets+7.6%+7.6%
Total Equity+9.0%+7.8%
Free Cash Flow−93.7%−30.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FDC₹376.55

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹6,131 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+3.0+6.8
EBITDA+6.6+11.3
Net Income+5.5+13.2
EPS (adj.)+5.5+13.2
Total Assets+7.6+7.6
Total Equity+9.0+7.8
Free Cash Flow-93.7-30.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.